Therapies for benign prostatic hyperplasia (BPH) may either improve or exacerbate sexual function with an ensuing impact on quality of life. Here we review a total of 73 papers on medical therapies for BPH with a focus on the effects of different pharmacological agents on sexual function. For example, certain a 1 -adrenergic receptor blockers may improve erectile function; however, ejaculatory dysfunction with one of these agents, tamsulosin, occurs at a rate of 4-18%, rising to 30% with long-term use. In addition, treatment with the 5a-reductase inhibitor finasteride is associated with problems of ejaculation (2.1-7.7%), erection (4.9-15.8%), and libido (3.1-5.4%). Such significant and undesirable complications in relation to sexual function produce a welldocumented negative impact on quality of life. Thus, optimal treatment for men with BPH requires the use of agents that demonstrate efficacy and safety with fewer sexual side effects.
Introduction
Benign prostatic hyperplasia (BPH) is an extremely common condition among elderly men, reaching a prevalence of approximately 70% in men over age 61 y and of greater than 90% in those over age 80 y. 1 Enlargement of the prostate may lead to subsequent obstruction of the bladder neck, which can produce lower urinary tract symptoms (LUTS) 2 or complications such as urinary tract infection, bladder stones, urinary retention, and renal failure. The bothersome nature of these symptoms generally prompts patients to seek medical attention. Some patients will require surgery for BPH, but even patients with severe symptoms may be treated medically, usually with a 1 -adrenergic receptor inhibitors or 5a-reductase inhibitors.
The side effects from medical therapy for BPH have been well described. For obvious reasons, cardiovascular effects, including dizziness, postural hypotension, and syncope, typically elicit the most concern from both patients and physicians. Ejaculatory and sexual dysfunction can also result from medical therapy for BPH and can have a significant impact on quality of life. In older patients, these medication-related side effects may be superimposed on age-related declines in sexual function. A recent multinational survey of more than 14 000 men between the ages of 50 and 80 y indicated that problems with all aspects of sexual function are strongly correlated with the severity of LUTS. 2 The severity of LUTS may be considered a risk factor for sexual dysfunction, similar to diabetes, hypertension, and depression. Sexual disorders and their bothersomeness have been found to be strongly correlated with both age and the severity of LUTS, independent of the presence of other comorbidities. 2 Urologists are quite familiar with many of the nonsexual side effects of the drugs used to treat BPH, particularly the a-adrenergic blockers, as these effects have been well documented. [3] [4] [5] [6] [7] [8] [9] The sexual side effects, particularly ejaculatory dysfunction, have been less well studied, and there is even less information on the differential effects of the medications, particularly any positive effects, on erectile function and sexual satisfaction. Issues of sexual function enter into the therapeutic decisions for BPH and LUTS and are an important measure of patient satisfaction with the outcome of treatment. In this article, we discuss the components of sexual dysfunction measurements in BPH, considering ejaculatory and erectile dysfunction as relevant factors. Using data we gathered from a review of literature published from 1966 to the present, we compare and contrast the two main classes of pharmacological therapy for BPH, a 1 -blockers and 5a-reductase inhibitors, particularly with regard to sexual dysfunction (including ejaculation disorders) and the impact of these side effects on quality of life. This information will assist the urologist in selecting optimal therapies for patients with BPH.
Components of quality of life in BPH
Lower urinary tract symptoms Several tools have been developed to measure the presence of LUTS in BPH and to assess the effects of these symptoms on quality of life. 10 The primary tools used to determine the presence of LUTS include the International Prostate Symptom Score (IPSS), the American Urological Association (AUA) Symptom Index, 11 the Danish Prostate Symptom Score (DAN-PSS), 12 and the International Continence Society questionnaire. 13 Other tools that measure the effect of LUTS on quality of life include the BPH Impact Index, 14 the UROLIFE Scale, 15 the BPH Health-related Quality of Life Survey, 16 and the bothersomeness question included in the IPSS (Bother Score).
Urologists are most familiar with the IPSS, which was modified in 1995 after an international consultation of BPH experts added one BPH-specific quality of life question. This question asks patients, 'If you had to live with your condition as it is now, how would you feel about it?' The question measures the extent to which the symptoms are bothersome. 17 It is the characteristic of being bothersome that determines whether LUTS affect quality of life. The development of symptoms to the point where they become bothersome is the most important predictor of failure of watchful waiting as a therapeutic option in men with BPH. 18 A number of studies using these tools have documented that LUTS can have a significant impact on quality of life in men with BPH, resulting in increased levels of bother and worry as well as interference with daily activities. [19] [20] [21] [22] Men with moderate to severe symptoms have reported four to six times the degree of bother and interference with daily activities and twice the level of worry as men with mild symptoms. 19 Severe BPH symptoms have been shown to correlate with serious worries and concerns about the urinary condition. 22 Among the more serious urinary conditions that significantly affect quality of life in patients with BPH are bladder stones, urinary retention, urinary tract infection, and renal failure.
Sexual dysfunction
In the ageing male, BPH and sexual dysfunction are often associated. Poor sexual function, which includes not only erectile and ejaculatory dysfunction but also decreased libido, is often considered to be a result of physical discomfort or anxiety, but it may actually be related to the physiological effects of the BPH itself. 23, 24 Data from the Prospective Randomised European Doxazosin and Combination (PREDICT) study showed that, in comparison with patients having IPSS scores o14 (indicating mild to moderate symptoms), men whose IPSS scores were 419 (indicating severe symptoms) had significantly decreased interest in sex, as well as problems keeping an erection and deriving satisfaction. 25 This effect was independent of age. Thus, it appears that bothersome urinary tract symptoms can directly impair patients' sexual satisfaction. The Multinational Survey of the Aging Male (MSAM-7) showed that 49% of men with LUTS reported erection difficulties, 48% had ejaculatory disturbance, and 7% had pain during sex. Ejaculation disorders, therefore, appear to be equally bothersome as erectile dysfunction. 2 The severity of urinary symptoms has been found to correlate with the degree of sexual dysfunction, as measured by a decrease in both the intensity of sexual desire, the frequency of sexual intercourse, the quality of erection, and the ejaculatory problems, independently of the age and other comorbidities. 26 These findings illustrate the need to take sexuality into account in initial evaluations of patients with BPH and in the choice of treatment.
Few studies have examined the impact of sexual dysfunction in sexually active men following therapy for BPH. It is especially important to evaluate this impact, since a recent study shows that men with BPH are already predisposed to sexual problems before they start therapy. 2 A report by Schou et al 27 found that, among the 54% of men with clinically significant LUTS (as measured by the DAN-PSS questionnaire) who had reduced ejaculatory volume, the related bother factor was minimal. Indeed, Emberton et al 28 have demonstrated a minimal effect of ejaculatory dysfunction on quality of life even after transurethral resection of the prostate, which carries a much higher risk for retrograde ejaculation than does medical management. In both of these studies, though, the mean age of the population was higher than in the randomized clinical trials for the a-blockers, which may explain the relatively low bother score for ejaculatory dysfunction in these settings.
Only one study has specifically examined the impact of ejaculatory dysfunction on quality of life following therapy for BPH. 29 Among 173 patients treated for BPH with a variety of interventional modalities, 45.5% of those who experienced loss of Sexual effects of medical therapy for benign prostatic hyperplasia DJ Carbone and S Hodges ejaculation or severe decrease in ejaculate volume reported that their sex life had deteriorated as a result of treatment. In contrast, only 18.6% of patients with a slight to moderate decrease in ejaculate volume and just 3.6% of men noting no change in ejaculate volume reported a deterioration in their sex life. Thus, deterioration of sexual activity was significantly associated with the severity of ejaculatory dysfunction (Po0.0001); this correlation was strongest in patients who were 69 y of age or younger (Po0.0001). Thus, these results suggest that patients with moderate to severe reduction in ejaculatory volume (particularly younger patients) may experience a significant and deleterious impact on quality of life. Although in clinical studies of the a-blockers the impact of abnormal ejaculation on quality of life appears to be outweighed by the benefits of the medication, further research is needed to evaluate with adequate tools the impact of this side effect of therapy and to optimize treatment for individual patients.
Physiology of male sexual function
An understanding of the physiology of erection and ejaculation, along with the importance of sexual function to men with BPH, is crucial to selecting the proper treatment strategies for patients with BPH and LUTS. Ejaculation consists of three phases: seminal emission, formation of a pressure chamber, and antegrade expulsion of fluid from the urethra. 30 Emission is the term given to the deposition of the ejaculate in the posterior urethra via the ejaculatory ducts. This process is under the control of the sympathetic nervous system. Efferent fibers responsible for seminal emission originate in the cerebral cortex (thalamus, spinothalamic centers) and proceed through the anterolateral columns to the thoracolumbar and sympathetic chain (T10 to L3). From these ganglia, postsynaptic adrenergic nerve fibers course through the superior hypogastric plexus overlying the aortic bifurcation en route to the end organs. Within the thin adventitial tissue of the end organs is another synaptic junction, the short adrenergic fibers, branches of which innervate the individual smooth muscle cells. 31 The pressure chamber is formed by simultaneous closure of the bladder neck and distal contraction of the external sphincter mechanism as the emission phase continues. Antegrade ejaculation results when the urogenital diaphragm opens and the ischiocavernous, bulbocavernous, and pelvic floor muscles contract in a rhythmic fashion. While contraction of these muscles is controlled by the somatic nervous system, somatic muscle control is part of the ejaculatory reflex, and the reflex itself is not thought to be under voluntary control. 32 
Medical therapy for BPH
Medical therapy for BPH consists primarily of treatment with two distinct classes of drugs, the a 1 -adrenergic receptor blockers and the 5a-reductase inhibitors. The scientific rationale for the use of a 1 -blockers in the therapy of BPH is based on the role of a 1 -adrenergic receptors in mediating smooth muscle relaxation, particularly at the bladder neck; overstimulation of these receptors leads to LUTS. 33 The nonsexual side effects of the a 1 -blockers have been well documented. A number of reports and metaanalyses have demonstrated that these medications may cause adverse events including dizziness, headache, asthenia, syncope, postural hypotension, and somnolence. [3] [4] [5] [6] [7] [8] [9] The role of 5a-reductase inhibitors in BPH therapy originated from the discovery that, in adult men with a congenital deficiency of the 5a-reductase enzyme, the prostate was nonpalpable. 34 Subsequently, finasteride, a 5a-reductase inhibitor, was found to block the conversion of testosterone to dihydrotestosterone. 35 In clinical studies, administration of finasteride resulted in a durable reduction of prostatic volume. 36, 37 The foregoing review of the physiology of ejaculation serves as a basis for understanding the mechanisms responsible for the ejaculatory and sexual side effects occurring with these two classes of drug treatment for BPH.
Ejaculation and others sexual disorders associated with medical therapy for BPH a 1 -Blockers Ejaculatory dysfunction. The presence and activity of a 1 -receptors in the prostate and uretha make a 1 -blockers a rational choice for the treatment of BPH. However, the impairment at the bladder neck, seminal vesicle, and/or vas deferens can modify the ejaculation phenomenon. Blockade of the areceptors in the bladder neck causes muscle relaxation, allowing semen to flow back into the bladder during climax (retrograde ejaculation). The risk of abnormal ejaculation from a-blocker therapy for BPH, while present, is much lower than that from surgical intervention for BPH. The Agency for Health Care Policy and Research has estimated a 6-55% likelihood of abnormal ejaculation following transurethral incision of the prostate, a 36-95% likelihood following open surgery, and a 25-99% likelihood following transurethral resection of the prostate. In contrast, the risk from a-blockade is generally less than 1%, although it can be higher with some agents, specifically tamsulosin (see below). 
The a-blockers vary in their pharmacological specificity for subtypes of a 1 -adrenergic receptors. The a 1A subtype appears to be the type that predominates at the bladder neck, in prostatic smooth muscle, seminal vesicle, and on the vas deferens and is involved in producing contraction. [38] [39] [40] However, there is some controversy about whether pharmacological selectivity translates into clinical uroselectivity, as the newer-generation ablockers have a lower vasodilatory side-effect profile. 41 Terazosin appears to be associated with a relatively low incidence of ejaculatory dysfunction. In the 1996 Veterans Administration study comparing placebo, terazosin, finasteride, and combination therapy, the incidence of ejaculatory dysfunction with terazosin was 0.3%. 42 In the Hytrin Community Assessment Trial (HYCAT), it was also low, 1.4%, but statistically significantly different from placebo (P ¼ 0.01). 43 With alfuzosin, one study has found no incidence of abnormal ejaculation. 44 Doxazosin has been poorly studied with respect to ejaculatory dysfunction. 45 In contrast to these agents is tamsulosin, which is highly selective for the a 1A -adrenoreceptor subtype 4, 46 and thus has been reported to produce symptomatic improvement of BPH without affecting blood pressure or heart rate and without requiring dose titration (although approximately 20% of patients do require the 0.8-mg dose). 47 Perhaps because of its higher pharmacological selectivity for a 1A -receptors in the bladder neck, seminal vesicles, and vas deferens however, tamsulosin is associated with a significant incidence of ejaculatory dysfunction. It is impossible to know actually if it is abejaculation or retrograde ejaculation. A study with tamsulosin in a rat model measuring bladder neck pressure and seminal vesicle pressure in response to electrostimulation of the hypogastric nerve showed that tamsulosin induced more deleterious effects on both of these pressures than did alfuzosin, when both drugs were given at doses sufficient to decrease urethral pressure. 48 Other characteristics of tamsulosin, such as central effect, may also be responsible for some of the differences observed in this study. Thus, the benefits of tamsulosin treatment must be balanced against the potential for an increase in sexual dysfunction.
Placebo-controlled clinical trials with tamsulosin have shown the incidence of ejaculatory disturbances to be significantly higher in tamsulosintreated patients than in placebo patients. In one trial, the incidence of ejaculatory dysfunction was 4.5% with tamsulosin vs 1.0% with placebo (P ¼ 0.045), 4 and in another, the incidence of abnormal ejaculation in the tamsulosin-treated patients was 6.0%, significantly higher than that in the placebo patients (Po0.001 ). 49 A 3-y European follow-up study reported a cumulative rate of ejaculatory dysfunction with tamsulosin of 5.4%, but only one patient (0.3%) discontinued the medication because of abnormal ejaculation. 50 In a combined analysis from double-blind clinical trials with tamsulosin, the frequency of overall abnormal ejaculation (including retrograde ejaculation, ejaculation failure, and ejaculation decrease) was 8.4% for the 0.4-mg dose and 18.1% for the 0.8-mg dose. 51 During a 64-week open extension of these doubleblind trials, abnormal ejaculation was observed in 30% of patients treated with tamsulosin. 52 One European study comparing the lower dose of tamsulosin (0.4 mg) with alfuzosin did not report such high incidences of ejaculatory dysfunction. 53 The reasons for the discrepancy between these results and those from the placebo-controlled trials are unclear. In this 12-week clinical trial, the incidence of ejaculatory dysfunction with tamsulosin was 0.8%, and with alfuzosin it was 0%, a difference that was not statistically significant.
Taken together, these clinical results indicate a low overall incidence of ejaculatory dysfunction with a 1 -blockers that are not selective for the a 1A subtype and a minimal discontinuation rate attributable to this particular adverse event.
Abnormal ejaculation is readily identified by noting a low ejaculate volume on semen analysis and checking the postejaculate urine for sperm. Several treatment options exist for retrograde ejaculation, one of which is withdrawal of the offending agent and replacement with a treatment for BPH that does not cause this side effect. In all of the trials cited above, cessation of the medication resulted in resolution of the symptoms of ejaculatory dysfunction. If the ejaculatory dysfunction is idiopathic, a number of oral therapies can be used (Table 1) . 31 Approximately one-third of men will respond to this form of therapy, although the sympathomimetic drugs listed may exacerbate the LUTS. 31 Erectile dysfunction and-impairment of sexual satisfaction. Except for the low risk of ejaculatory disorders that may be induced by treatment with ablockers, most data suggest a beneficial role for a-blockers with regard to all aspects of sexual function. The tools actually available do not take into account clearly the ejaculation phenomenon; they are more focused on erection dimension. The European study discussed above demonstrated improved total sexual function in patients treated with tamsulosin compared with placebo, 53 and a study of alfuzosin treatment in a general practice setting recorded a significant improvement in patients' perceived sexuality after 12 months of treatment. 54 Two mechanisms have been proposed to explain patients' improved sexual functioning following treatment for LUTS with a-blockers. First, as the symptoms become less bothersome, patients may feel less 'disabled' by their urinary symptoms and may thus be better able to enjoy other facets of life Sexual effects of medical therapy for benign prostatic hyperplasia DJ Carbone and S Hodges without feeling inhibited or limited. 55 Alternatively, inhibition of the a 1 -and a 1D -adrenoreceptor subtypes that predominate in cavernosal smooth muscle should facilitate erection. 56 The mechanism by which a-blockers affect the erectogenic response is via relaxation of the smooth muscle in the penile arteries or the corpora cavernosum, thus improving the inflow of blood. The erectogenic properties of the a-adrenoreceptor antagonist phentolamine, first suggested by Zorgniotti and Lefleur, 57 are well established; indeed, the combination of intracavernosal phentolamine and papaverine was the most commonly used pharmacological approach to erectile dysfunction in the United States until the advent of alprostadil (Caverject s ; Upjohn; Kalamazoo, MI, USA) and later sildenafil (Viagra s ; Pfizer; New York, NY, USA). Concentration-dependent relaxation of corpus cavernosum muscle strips was demonstrated in isometric tension studies with prazosin, tamsulosin, doxazosin, and terazosin, with tamsulosin being the most potent. 58 Clinical efficacy of newer a-blockers for erectile dysfunction has also been reported. In a study of 38 men with erectile dysfunction treated with doxazosin in combination with intracavernosal therapy, the addition of the oral a-blocker had a beneficial effect in patients for whom intracavernosal therapy alone had failed. 59 Among the patients receiving the combined regimen, 57.9% achieved a significant therapeutic response. These studies provide evidence that treatment of LUTS with a-blockers in men with BPH may in fact improve erectile function in most patients.
Preservation and potential improvement of erectile function has a significant impact on quality of life in these patients. It is well established that erectile dysfunction contributes to anxiety, depression, loss of self-esteem, and diminished quality of life. 60 Conversely, experience with sildenafil demonstrates that improved erectile function results in improved quality of life, contributing to a statistically significant improvement in emotional wellbeing. 61 It stands to reason, then, that medical therapy for BPH that at least preserves, and potentially improves, erectile function would have a positive effect on quality of life.
5a-Reductase inhibitors
Ejaculatory dysfunction. Ejaculation disorders associated with finasteride range from decreased volume of the ejaculate to failure of ejaculation. Randomized clinical trials in men with symptomatic BPH demonstrate an incidence of ejaculatory dysfunction associated with finasteride ranging from a low of 2.1% 62 to a high of 7.7%. 36, [63] [64] [65] However, as with the ejaculatory dysfunction associated with a-blocker therapy, only a small percentage of patientsF1.5% in one study 63 Fhave been shown to withdraw from therapy because of this adverse effect. Again, the tendency of patients not to withdraw from therapy because of ejaculatory dysfunction does not necessarily imply that ejaculatory disorders are not bothersome, but rather it suggests that the benefits of therapy outweigh the deleterious impact of ejaculatory dysfunction on quality of life. An alternative but not mutually exclusive explanation is that the patient may be unware that this symptom is related to therapy. Ejaculatory dysfunction, like other sexual dysfunctions associated with finasteride, tends to occur 31 Sexual effects of medical therapy for benign prostatic hyperplasia DJ Carbone and S Hodges earlier rather than later in the therapeutic regimen. Most subjects experience the onset of symptoms within the first 9 months of treatment. 66 Erectile dysfunction and decreased libido. Nearly all trials involving finasteride in the treatment of LUTS resulting from BPH demonstrate a statistically significant increase in erectile dysfunction, suggesting a deleterious impact on quality of life. In the PROSPECT trial, involving 472 men who completed 2 y of therapy with finasteride, the incidence of erectile dysfunction was 15.8% in the treatment arm vs 6.3% in the placebo arm (Pr0.01%). 67 Other studies have shown a lower incidence of erectile dysfunction, although an incidence that was still statistically significant. For example, in the Finasteride Study, the incidence of erectile dysfunction was 4.9%, a statistically significant difference vs placebo. 68 For the reasons discussed earlier, a statistically significant increase in the incidence of erectile dysfunction is correlated with a significant reduction in quality of life.
Finasteride has also been shown to impair libido. In randomized clinical trials, the incidence of impaired libido with finasteride has ranged from 3.1 63 to 5.4%. 65 Currently, dutasteride, an inhibitor of both the type 1 and type 2 5a-reductase isozymes, is being investigated for the treatment of BPH. Dutasteride's dual inhibition has produced nearly complete suppression of serum dihydrotestosterone in healthy male subjects. 69 Clinical trials conducted thus far have not addressed sexual and ejaculatory dysfunction.
70-72

Conclusions
Medical therapy for LUTS resulting from BPH can have a significant and deleterious impact on quality of life through adverse effects on all aspects of sexual function, including ejaculatory and erectile function. Physician awareness of these complications and a willingness to discuss them with the patient can minimize their impact. With the advent of sildenafil, a number of studies have demonstrated the benefit of physician-patient discussion of sexual function. Openness on the part of the clinician allows the patient to feel comfortable when discussing his sexual function in detail and improves the physician-patient relationship. 73 Discussion of sexual function can also help identify other coexisting medical conditions. For example, ejaculatory dysfunction resulting from medical therapy for BPH in a young man may cause infertility. This potential complication is often not discussed with patients prior to the intiation of therapy, and they may thus be unaware of the impact of treatment on fertility. If the condition is not discussed with the patient, the diagnosis may be missed, resulting in a significant disservice to the patient and his partner. Moreover, the ejaculation domain is often underestimated and the sexuality is often focused on the erection. Erectile dysfunction may be a marker also for other conditions, particularly cardiovascular disease. Recent studies have clearly demonstrated evidence of occult coronary artery disease, hypertension, and previously undiagnosed hyperlipidemia in men presenting with erectile dysfunction. Thus, it is incumbent upon the physician to ask about patients' sexual health, particularly in patients undergoing medical therapy for BPH.
